News | July 28, 2021
Granules India Q1FY22 consolidated net profit at Rs. 120.20 Cr
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
7.94 crore doses were made available to the states in May 2021
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated
